Skip to search formSkip to main contentSkip to account menu

istradefylline

Known as: 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Adenosine A2 Receptor AntagonistsPurines

Narrower (1)

KW 6002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Treatment with istradefylline for postural abnormalities in Parkinson's disease.
INTRODUCTION In the current edition, Fujioka and colleagues report on four Japanese patients with Parkinson disease (PD) and… 
2019
2019
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
Adenosine is a neuromodulator that regulates the body’s response to dopamine and another neurotransmitter in the brain that is… 
2018
2018
Clinical Efficacy of Istradefylline for Depression in Parkinson’s Disease
Background: Parkinson’s disease (PD) is a common movement disorder with a wide range of non-motor symptoms. Depression is one of… 
2017
2017
Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease
Background: Istradefylline is a selective adenosine A2A receptor antagonist approved for Parkinson’s disease (PD) patients with… 
Review
2017
Review
2017
The therapy of the motor symptoms in the advanced stage of Parkinson's disease.
This review focuses on the medical treatment strategies for the advanced stages of Parkinson disease (PD), according to the… 
2016
2016
[OP.8C.04] THE FLOW DETECTION ROLE OF THE VASCULAR EPITHELIAL SODIUM CHANNEL (ENAC) IN AN EXPERIMENTAL MODEL OF HYPERTENSION: THE NOVEL TARGET FOR SPIRONOLACTONE THERAPY?
Objective: Hypertension (HTN) impairs the regulation of blood flow leading to cardiovascular morbidity and mortality. A “new… 
2014
2014
Istradefylline synthesis process
The invention discloses an istradefylline synthesis process comprising the following steps: a compound I is prepared from 1,3… 
2010
2010
Synthesis of Antiparkinsonian Agent Istradefylline
Istradefylline, the antiparkinsonian agent, was synthesized from vanillin via methylation, Knoevenagel condensation and… 
2008
2008
Istradefylline: An adenosine receptor antagonist for the treatment of Parkinson disease
Istradefylline, a highly selective adenosine A2A receptor antagonist, is a new agent being investigated for the adjunctive… 
2008
2008
Istradefylline reduces motor fluctuations in Parkinson's disease
enhanced when the molecules were adminis­ tered in viscous solutions: the dispersal area of pristine MNPs administered in saline…